Buy Longidase suppositories 3000 IU 20 pcs
  • Buy Longidase suppositories 3000 IU 20 pcs


NPO Petrovax Farm
789 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Longidaza - a drug with proteolytic activity.

Possesses enzymatic proteolytic (hyaluronidase) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory action.

Prolonged action is achieved by covalent binding of the enzyme with a physiologically active high molecular weight carrier (activated derivative of poly-1.4-ethylene piperazine N-oxide, an analog of polyoxidonium), which has its own pharmacological activity.

Longidaza exhibits anti-fibrotic properties, weakens the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor alpha), increases the humoral immune response and resistance of the organism to infection.

The pronounced anti-fibrotic properties of Longidaza are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors.

The enzymatic activity of Longidaza remains when heated to 37 ° C for 20 days, while native hyaluronidase begins to lose its activity during the same day under the same conditions.

In the preparation of Longidaza, the simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier is provided that is capable of binding the enzyme inhibitors released during the hydrolysis of the matrix components and stimulants of collagen synthesis (iron ions, copper, heparin). Due to these properties, Longidaza has not only the ability to depolymerize the connective tissue matrix in fibro-granulomatous formations, but also to suppress the reverse regulatory response aimed at the synthesis of components of the connective tissue.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C 1 acetylglycosamine and C 4 glucuronic or induuro acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water decreases, metal ions increase, the permeability of tissue barriers increases, fluid movement in the intercellular space is facilitated, and elasticity increases connective tissue, which is manifested in a decrease in swelling of the tissue, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and REPRESENTATIONS their formation, reduction of adhesions.

Biochemical, immunological, histological, and electron microscopic studies have shown that Longidaza does not damage normal connective tissue, but causes destruction of the composition and structure of the connective tissue in the area of ​​fibrosis.

Longidaza does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The use of Longidaza in therapeutic doses during or after surgical treatment does not cause deterioration of the postoperative period or progression of the infectious process; does not slow down the recovery of bone tissue.


Adults and adolescents over 12 years of age as monotherapy and as part of a complex therapy of diseases involving connective tissue hyperplasia (including against the background of the inflammatory process).

Longidaza is also used to increase the bioavailability of antibiotic therapy in urology, gynecology, dermatology, surgery and pulmonology.

In urology:

  • Chronic prostatitis.
  • Interstitial cystitis.
  • Strictures of the urethra and ureters.
  • Peyronie's Disease.
  • The initial stage of benign prostatic hyperplasia.
  • Prevention of the formation of scars and strictures after surgical interventions on the urethra, bladder, ureters.

In gynecology:

  • Prevention and treatment of adhesions in the pelvis for chronic inflammatory diseases of the internal genital organs.
  • Prevention and treatment of adhesions in the pelvis after gynecological manipulations (including artificial abortions, previous surgical interventions on the pelvic organs).
  • Intrauterine synechia.
  • Tubal-peritoneal infertility.
  • Chronic endomyometritis.

In dermatology and venereology:

  • Limited scleroderma.
  • Prevention of fibrous complications of sexually transmitted infections.

In surgery:

  • Prevention and treatment of adhesions after surgery on the abdominal organs.
  • Prolonged wounds.

In pulmonology and phthisiology:

  • Pneumofibrosis.
  • Siderosis.
  • Tuberculosis (cavernous-fibrous, infiltrative, tuberculoma).
  • Interstitial pneumonia.
  • Fibrosing alveolitis
  • Pleurisy.

Longidaza® is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Longidaza® NPO Petrovax Farm Russia suppositories
Longidaza® NPO Petrovax Farm Russia lyophilisate

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Rectally, 1 suppository 1 time per day after bowel cleansing.

Vaginally, 1 time per day (overnight) 1 suppository is inserted into the vagina in the supine position.

Longidase® 3000 ME suppositories are recommended for a course of 10 to 20 administrations.

The regimen is adjusted depending on the severity, stage and duration of the disease: Longidaza® appointed every other day or with breaks of 2-3 days.

Recommended regimens and doses:

  • in urology: 1 suppository every other day - 10 injections, then in 2–3 days - 10 injections, with a total course of 20 suppes .;
  • in gynecology: rectally or vaginally, 1 suppository in 2 days - 10 injections, then, if necessary, supportive therapy is prescribed;
  • in dermatovenerology: on the suppository in 1–2 days - 10–15 injections;
  • in surgery: on the suppository in 2–3 days - 10 injections;
  • in pulmonology and phthisiology: on the suppository in 2–4 days - 10–20 injections.

If necessary, re-course of Longidaza is recommended.® no earlier than 3 months or long-term supportive therapy - 1 suppository 1 time every 5–7 days for 3-4 months.

Adverse reactions

Seldom- allergic reactions with increased individual sensitivity.

Carefully and no more than 1 time per week to use in patients with renal insufficiency, pulmonary hemorrhages in history.

Drug interactions

With the use of Longidaza in patients receiving salicylates, cortisone, ACTH, estrogen or antihistamine drugs in high doses, the effectiveness of the enzyme hyaluronidase can be reduced.

When prescribed in combination with other drugs, consideration should be given to the possibility of increasing their absorption (bioavailability) and enhancing systemic action.

Pregnancy and Lactation

The drug is contraindicated for use in pregnancy.

Data on the safety of the drug during lactation is not provided.

Longidaza has no embryotoxic and teratogenic effects.

Special instructions

When applied against the background of exacerbation of foci of infection to prevent the spread of infection, prescribe under the cover of antimicrobial agents.

With the development of an allergic reaction should immediately discontinue the use of Longidaza.

Longidaza does not have a mutagenic and carcinogenic effect.

With caution and no more than 1 time per week to apply in patients with renal insufficiency.

  • Brand name: Longidaza
  • Active ingredient: bovhyaluronidase azoximer
  • Dosage form: Suppositories
  • Manufacturer: Petrovax
  • Country of Origin: Russia

Customers who bought this product also bought:


Price $18.35


Price $29.25

8 other products in the same category: